Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.53 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.53 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 8/20 | 0.50 |
| ▸ | CA1 | P00915 | 8/20 | 0.50 |
| ▸ | CA2 | P00918 | 8/20 | 0.50 |
| ▸ | CA9 | Q16790 | 8/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.47 |
| ▸ | PYGB | P11216 | 1/20 | 0.47 |
| ▸ | AMY2A | P04746 | 1/20 | 0.46 |
| ▸ | FGF1 | P05230 | 1/20 | 0.45 |
| ▸ | FGF2 | P09038 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21894588 | 1.00 | LGALS8 (0.53) | LGALS8LGALS3LGALS4CA12CA1 | |
| SCHEMBL23617758 | 1.00 | LGALS8 (0.53) | LGALS8LGALS3LGALS4CA12CA1 | |
| SCHEMBL22296782 | 1.00 | LGALS8 (0.53) | LGALS8LGALS3LGALS4CA12CA1 | |
| SCHEMBL23735640 | 1.00 | LGALS8 (0.53) | LGALS8LGALS3LGALS4CA12CA1 | |
| SCHEMBL21698210 | 1.00 | LGALS8 (0.53) | LGALS8LGALS3LGALS4CA12CA1 | |
| SCHEMBL23430833 | 1.00 | LGALS8 (0.53) | LGALS8LGALS3LGALS4CA12CA1 | |
| SCHEMBL18976778 | 0.90 | MEN1 (0.49) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL22296747 | 0.87 | MEN1 (0.45) | LGALS8LGALS3LGALS4CA12CA1 | |
| SCHEMBL16221568 | 0.86 | LGALS8 (0.51) | LGALS8LGALS3LGALS4CA12CA1 | |
| SCHEMBL22372512 | 0.85 | LGALS8 (0.56) | LGALS8LGALS3LGALS4CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3862362-A2 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3845547-A1 | GALNAC3 CONJUGATED MODIFIED OLIGONUCLEOTIDE FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3828275-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3757215-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3137091-B1 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3730619-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS | Ionis Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3690049-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3633039-A1 | COMPOSITIONS AND METHODS | Ionis Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3608406-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3564374-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS | Ionis Pharmaceuticals, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| WO-2015042447-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179625-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179629-A2 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | LGALS8 28/4885LGALS3 19/4885LGALS4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.